3D printing company Stratasys (NASDAQ: SSYS) reported Q1 CY2026 results topping the market’s revenue expectations, but sales fell by 2.5% year on year to $132.7 million. The company’s full-year revenue guidance of $570 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP loss of $0.01 per share was $0.01 above analysts’ consensus estimates.
Is now the time to buy SSYS? Find out in our full research report (it’s free for active Edge members).
Stratasys (SSYS) Q1 CY2026 Highlights:
- Revenue: $132.7 million vs analyst estimates of $131.7 million (2.5% year-on-year decline, 0.8% beat)
- Adjusted EPS: -$0.01 vs analyst estimates of -$0.02 ($0.01 beat)
- Adjusted EBITDA: -$3.22 million vs analyst estimates of $1.51 million (-2.4% margin, significant miss)
- The company reconfirmed its revenue guidance for the full year of $570 million at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $0.12 at the midpoint
- EBITDA guidance for the full year is $27.5 million at the midpoint, above analyst estimates of $23.98 million
- Operating Margin: -20%, down from -9.1% in the same quarter last year
- Market Capitalization: $735.9 million
StockStory’s Take
Stratasys delivered first quarter results that topped investor expectations, with the company’s revenue and adjusted EPS both beating analyst estimates. Management attributed the year-over-year revenue decline primarily to continued caution in customer capital spending and extended purchasing cycles, especially for 3D printers. CEO Yoav Zeif emphasized the stability provided by recurring revenue from consumables and customer support, but acknowledged, “printer purchasing time lines remained extended as customers exercise capital discipline amid ongoing global uncertainty.” The quarter’s performance was also impacted by higher tariff expenses and foreign exchange headwinds, which weighed on margins.
Looking forward, Stratasys’ guidance is anchored by anticipated demand in aerospace and defense, ongoing expansion in dental markets, and new material and software offerings. Management expects sequential revenue growth throughout the year, citing a robust deal pipeline—particularly in defense—as well as regulatory milestones like the CE Class IIa certification for TrueDent Resin in Europe. Zeif stated, “We have built multiple opportunities to generate profitable growth, both through inorganic and organic opportunities, focusing on our position in high requirement use cases as we capitalize on the increased demand for additive manufacturing solutions.”
Key Insights from Management’s Remarks
Management identified aerospace and defense demand, new regulatory milestones in dental, and material innovations as key drivers behind recent results and forward guidance.
-
Aerospace and defense momentum: Stratasys’ strongest growth came from its parts manufacturing division, Stratasys Direct, which recorded over 23% organic growth year-over-year. Management highlighted increased U.S. Department of War investment in additive manufacturing, with Stratasys Direct selected for the Joint Additive Manufacturing Acceptability IV pilot program. The company’s established presence in defense—serving as a program of record for the U.S. Air Force and major OEMs—has enabled it to ship over 100,000 parts annually, moving beyond prototyping into full-scale production.
-
Dental market expansion: The TrueDent Resin achieved CE Class IIa certification in Europe, making it the first polychromatic monolithic 3D printed denture solution at this regulatory level. This upgrade broadens TrueDent’s use to include long-term intraoral removables and crowns, opening access to a European dental market projected at $2.45 billion by 2028. Management sees this as a first-mover advantage to deepen penetration in European dental labs and clinics.
-
Material and software advancements: The company launched ULTEM 1010 resin for the F3300 printer, enabling production of aerospace-grade, high-temperature parts. On the software side, Stratasys introduced measurement-based warped adaptive modeling in GrabCAD Print Pro, which automatically corrects warping for complex parts, reducing iterative cycles and improving user experience for DLP platforms.
-
Recurring revenue stability: Despite a decline in printer sales, recurring revenues from consumables and customer support provided a measure of stability. Management sees these streams as a foundation for weathering periods of delayed capital spending.
-
Tariff and FX pressures: The company’s margins were negatively affected by $2.4 million in incremental tariff expenses and $3.1 million from foreign currency fluctuations, particularly due to the strengthening Israeli shekel. Management cited these pressures as the primary drivers behind the year-over-year contraction in operating margin.
Drivers of Future Performance
Stratasys anticipates growth will be driven by expanding defense and dental opportunities, complemented by new materials and software, but faces ongoing cost headwinds.
-
Defense sector pipeline: Management expects increased defense spending and new programs to drive hardware and parts revenue. CEO Yoav Zeif pointed to sustained demand for production parts and tooling in aerospace, drones, and munitions, with Stratasys Direct serving as an early indicator for broader OEM adoption. The company anticipates the defense vertical will be a primary growth driver, especially in the second half of the year as large contracts are executed.
-
Dental regulatory expansion: The upgraded certification of TrueDent in Europe positions Stratasys to capture a larger share of the dental market, which favors high-complexity, biocompatible 3D printed solutions. Management believes its first-mover advantage and ongoing product improvements will allow for “exceptional growth” in this segment as adoption accelerates across new applications.
-
Margin headwinds and investment needs: Tariff expenses and foreign exchange volatility are expected to continue impacting margins, while the company plans to leverage its debt-free balance sheet to pursue inorganic growth and invest in high-requirement applications. Management cautioned that customer capital discipline could persist in the near term, but sees operating cash flow generation as a support for future investments.
Catalysts in Upcoming Quarters
In the quarters ahead, the StockStory team will monitor (1) the conversion of defense contracts into hardware and system sales, (2) the pace of adoption for TrueDent and its impact on European dental market share, and (3) the company’s ability to offset tariff and foreign exchange pressures through operational improvements. Execution against these milestones will be crucial for translating pipeline momentum into sustained growth.
Stratasys currently trades at $8.46, down from $9.25 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
